Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity

Pathological neovascularization in retinopathy of prematurity (ROP) can cause visual impairment in preterm infants. Current ROP treatments which are not preventative and only address late neovascular ROP, are costly and can lead to severe complications. We showed that topical 0.1% dexamethasone eye drops administered prior to peak neovessel formation prevented neovascularization in five extremely preterm infants at high risk for ROP and suppressed neovascularization by 30% in mouse oxygen-induced retinopathy (OIR) modeling ROP. In contrast, in OIR, topical dexamethasone treatment before any neovessel formation had limited efficacy in preventing later neovascularization, while treatment after peak neovessel formation had a non-statistically significant trend to exacerbating disease. Optimally timed topical dexamethasone suppression of neovascularization in OIR was associated with increased retinal mitochondrial gene expression and decreased inflammatory marker expression, predominantly found in immune cells. Blocking mitochondrial ATP synthetase reversed the inhibitory effect of dexamethasone on neovascularization in OIR. This study provides new insights into topical steroid effects in retinal neovascularization and into mitochondrial function in phase II ROP, and suggests a simple clinical approach to prevent severe ROP.

Authors

Institutions

Publication Details

Journal
Angiogenesis
Published
2024-09-17
DOI
https://doi.org/10.1007/s10456-024-09948-2
Citations
6
Primary Topic
Retinopathy of Prematurity Studies
Type
article
Field-Weighted Citation Impact
2.43

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity

Gaël Cagnone, Myriam Boeck, Zhongjie Fu, Sasha A. Singh et al.
6 citations
Angiogenesis
Retinopathy of Prematurity Studies
2.43
article

Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity

Gaël Cagnone, Myriam Boeck, Zhongjie Fu, Sasha A. Singh, Ann Hellström, Pia Lundgren, Katherine Neilsen, Yohei Tomita, Hitomi Yagi, Masanori Aikawa, Kazuno Negishi, Jean‐Sébastien Joyal, Taku Kasai, Lois E. H. Smith, Mariya Petrishka-Lozenska, Jeff Lee, Chaomei Wang
article en
6 citations

Abstract

Pathological neovascularization in retinopathy of prematurity (ROP) can cause visual impairment in preterm infants. Current ROP treatments which are not preventative and only address late neovascular ROP, are costly and can lead to severe complications. We showed that topical 0.1% dexamethasone eye drops administered prior to peak neovessel formation prevented neovascularization in five extremely preterm infants at high risk for ROP and suppressed neovascularization by 30% in mouse oxygen-induced retinopathy (OIR) modeling ROP. In contrast, in OIR, topical dexamethasone treatment before any neovessel formation had limited efficacy in preventing later neovascularization, while treatment after peak neovessel formation had a non-statistically significant trend to exacerbating disease. Optimally timed topical dexamethasone suppression of neovascularization in OIR was associated with increased retinal mitochondrial gene expression and decreased inflammatory marker expression, predominantly found in immune cells. Blocking mitochondrial ATP synthetase reversed the inhibitory effect of dexamethasone on neovascularization in OIR. This study provides new insights into topical steroid effects in retinal neovascularization and into mitochondrial function in phase II ROP, and suggests a simple clinical approach to prevent severe ROP.

AngiogenesisVol. 27(4)
Brigham and Women's Hospital (US), Boston Children's Hospital (US), Harvard University (US), Keio University (JP), Sahlgrenska University Hospital (SE), University Medical Center Freiburg (DE), Centre Hospitalier Universitaire Sainte-Justine (CA), Université de Montréal (CA), University of Gothenburg (SE)
Boston Children's Hospital, Massachusetts Lions Eye Research Fund, Ögonfonden, Kowa Company, Svenska Forskningsrådet Formas, Vetenskapsrådet, National Institutes of Health, Intellectual and Developmental Disabilities Research Center
Good health and well-being
Openalex Percentile: Top 11%
Retinopathy of Prematurity Studies
2.43
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.